We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When Geno Germano left Pfizer in 2016, he headed to the synthetic biology firm Intrexon, but left relatively quickly as a restructuring changed the startup’s focus. Now, the pharma veteran has taken the helm at Elucida Oncology